or Try an Advanced Search...

    Technical Analysis for NKTX - Nkarta, Inc.

    Grade Last Price % Change Price Change
    F 3.19 3.57% 0.11
    NKTX closed up 3.57 percent on Friday, November 1, 2024, on 83 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 7
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NKTX trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 3.57%
    Wide Bands Range Expansion 3.57%
    Below Lower BB Weakness 3.57%
    Down 3 Days in a Row Weakness 3.57%
    Lower Bollinger Band Touch Weakness 3.57%
    Older End-of-Day Signals for NKTX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 19 hours ago
    Possible Inside Day about 19 hours ago
    Up 5% about 23 hours ago
    Up 3% about 23 hours ago
    Up 2% about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    NKTX Chart by TradingView
    Basic chart:

    Profile

    Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Biology Immune System Immunotherapy Cancer Treatment Tumor Gene Therapy Lymphoma Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Therapies For Cancer Chimeric Antigen Receptor Antigen CD19 Tumor Cell

    Is NKTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 Nkarta (NKTX) Stock: Looking For Upside
    Oct 31 Nkarta: Catalysts Ahead, But Competition In Cell Therapy Too (Rating Downgrade)
    Oct 18 Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
    Oct 9 Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
    Sep 3 Nkarta to Participate in Upcoming Investor Conference
    Aug 14 Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients
    Aug 14 Why Nkarta Stock Is Soaring Today
    Aug 14 Nkarta upgraded at Raymond James on valuation
    Aug 14 Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Aug 14 Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
    See more NKTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.24
    52 Week Low 1.9
    Average Volume 605,573
    200-Day Moving Average 7.18
    50-Day Moving Average 4.61
    20-Day Moving Average 3.77
    10-Day Moving Average 3.57
    Average True Range 0.32
    RSI (14) 32.43
    ADX 23.3
    +DI 16.72
    -DI 29.58
    Chandelier Exit (Long, 3 ATRs) 3.59
    Chandelier Exit (Short, 3 ATRs) 4.04
    Upper Bollinger Bands 4.49
    Lower Bollinger Band 3.06
    Percent B (%b) 0.09
    BandWidth 37.93
    MACD Line -0.37
    MACD Signal Line -0.33
    MACD Histogram -0.0385
    Fundamentals Value
    Market Cap 156.54 Million
    Num Shares 49.1 Million
    EPS -2.50
    Price-to-Earnings (P/E) Ratio -1.28
    Price-to-Sales 1000000.00
    Price-to-Book 1.84
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.42
    Resistance 3 (R3) 3.42 3.34 3.38
    Resistance 2 (R2) 3.34 3.28 3.34 3.37
    Resistance 1 (R1) 3.26 3.24 3.30 3.27 3.36
    Pivot Point 3.18 3.18 3.20 3.18 3.18
    Support 1 (S1) 3.11 3.12 3.15 3.11 3.02
    Support 2 (S2) 3.03 3.09 3.03 3.01
    Support 3 (S3) 2.95 3.03 3.00
    Support 4 (S4) 2.96